Aldeyra Therapeutics, Inc.
ALDX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.00 | 0.23 | -0.59 | 0.50 |
| FCF Yield | -3.72% | -3.62% | -4.06% | -2.49% |
| EV / EBITDA | -22.12 | -32.99 | -16.87 | -18.42 |
| Quality | ||||
| ROIC | -14.35% | -13.13% | -19.21% | -16.02% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.91 | 0.88 | 1.26 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 31.39% | -3.60% | -50.93% | 39.69% |
| Safety | ||||
| Net Debt / EBITDA | 2.78 | 3.71 | 2.57 | 3.60 |
| Interest Coverage | -21.61 | -21.56 | -35.21 | -33.67 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,102.93 | -511.45 | -132.83 | -267.08 |